中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2009年
3期
167-169
,共3页
崔甜甜%吴少雄%韩非%卢丽霞%黄劭敏%邓小武%卢泰祥%赵充
崔甜甜%吳少雄%韓非%盧麗霞%黃劭敏%鄧小武%盧泰祥%趙充
최첨첨%오소웅%한비%로려하%황소민%산소무%로태상%조충
鼻咽肿瘤/放射疗法%放射疗法,调强%腮腺功能
鼻嚥腫瘤/放射療法%放射療法,調彊%腮腺功能
비인종류/방사요법%방사요법,조강%시선공능
Nasopharyngeal neoplasms/radiotherapy%Radiotherapy,intensity-modulated%Parofid function
目的 评价调强放疗对鼻咽癌患者腮腺功能的影响.方法 搜集2003年前2年内83例初治患者放疗前、放疗结束时、放疗后6个月和1、2、3、4、5年的口干变化情况的资料,通过分析其与腮腺受照剂量关系来评价调强放疗对腮腺功能影响.结果 共入组83例,其中Ⅰ期4例,Ⅱ期31例,Ⅲ期31例,ⅣA期17例;16例接受放化综合治疗.中位随访时间65个月,5年局部和区域控制率为96%和95%,总生存率为80%.放疗后7个时间段轻和中度口干发生率分别为42%、51%、71%、77%、58%、38%、26%和52%、53%、21%、8%、3%、2%、2%,无重度口干.双侧腮腺受照射平均剂量为34.34 Gy.放疗后6个月口干分级与腮腺平均受照剂量呈正相关,双侧腮腺50%体积受照剂量是放疗后6个月时口干分级的独立影响因素.当腮腺平均剂量≤33 Gy和D50≤29 Gy时,腮腺功能可得到较好地保护.结论 调强放疗在提高鼻咽癌局部和区域控制率的同时,降低了腮腺的受照剂量,减少了腮腺功能的损伤.
目的 評價調彊放療對鼻嚥癌患者腮腺功能的影響.方法 搜集2003年前2年內83例初治患者放療前、放療結束時、放療後6箇月和1、2、3、4、5年的口榦變化情況的資料,通過分析其與腮腺受照劑量關繫來評價調彊放療對腮腺功能影響.結果 共入組83例,其中Ⅰ期4例,Ⅱ期31例,Ⅲ期31例,ⅣA期17例;16例接受放化綜閤治療.中位隨訪時間65箇月,5年跼部和區域控製率為96%和95%,總生存率為80%.放療後7箇時間段輕和中度口榦髮生率分彆為42%、51%、71%、77%、58%、38%、26%和52%、53%、21%、8%、3%、2%、2%,無重度口榦.雙側腮腺受照射平均劑量為34.34 Gy.放療後6箇月口榦分級與腮腺平均受照劑量呈正相關,雙側腮腺50%體積受照劑量是放療後6箇月時口榦分級的獨立影響因素.噹腮腺平均劑量≤33 Gy和D50≤29 Gy時,腮腺功能可得到較好地保護.結論 調彊放療在提高鼻嚥癌跼部和區域控製率的同時,降低瞭腮腺的受照劑量,減少瞭腮腺功能的損傷.
목적 평개조강방료대비인암환자시선공능적영향.방법 수집2003년전2년내83례초치환자방료전、방료결속시、방료후6개월화1、2、3、4、5년적구간변화정황적자료,통과분석기여시선수조제량관계래평개조강방료대시선공능영향.결과 공입조83례,기중Ⅰ기4례,Ⅱ기31례,Ⅲ기31례,ⅣA기17례;16례접수방화종합치료.중위수방시간65개월,5년국부화구역공제솔위96%화95%,총생존솔위80%.방료후7개시간단경화중도구간발생솔분별위42%、51%、71%、77%、58%、38%、26%화52%、53%、21%、8%、3%、2%、2%,무중도구간.쌍측시선수조사평균제량위34.34 Gy.방료후6개월구간분급여시선평균수조제량정정상관,쌍측시선50%체적수조제량시방료후6개월시구간분급적독립영향인소.당시선평균제량≤33 Gy화D50≤29 Gy시,시선공능가득도교호지보호.결론 조강방료재제고비인암국부화구역공제솔적동시,강저료시선적수조제량,감소료시선공능적손상.
Objective To evaluate the effect of intensity-modulated radiation therapy(IMRT) on parotid function in nasopharyngeal carcinoma(NPC). Methods Eighty-three NPC patients received prima-ry IMRT between 2001 and 2003. Xerostomia before radiotherapy, at the end of radiotherapy, at 6-month, 1-,2-,3-,4- and 5-year after radiotherapy were investigated, respectively. The relation between xerostomia and parotid dose distribution was analyzed. Results Of all the patients,4,31,31 and 17 had stage Ⅰ,Ⅱ,Ⅲ and ⅣA disease, respectively. Sixteen patients received chemo-radiotherapy. The median followed-up time was 65 months. The 5-year local control and regional control rate were 96% and 95% ,respectively. The 5-year overall survival rate was 80%. The mild xerostomia rate at the seven time points was 42%, 51%, 71%, 77%, 58%, 38% and 26%. The corresponding moderate xerostomia rate was 52%, 53%, 21%,8%, 3%, 2% and 2%, respectively. No serious xerostomia was observed. The mean dose of the bilateral parotid glands was 34.34 Gy. Xerostomia at 6-month after radiotherapy was positively correlated with the mean dose of the parotid glands, and D50 was the independent factor in predicting the xerostomia. Parotid function was well protected when the mean dose and D50 were no more than 33 Gy and 29 Gy,respectively. Conclusions IMRT can improve the local-regional control of NPC and protect the parotid glands from radiation-induced in-jury.
